Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chloroquine as Adjuvant to Standard Anti-TB Therapy in Healthy Volunteers
NCT05443178Phase 1Recruiting
- Sponsor
- University of Zurich
- Start
- Jan 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of chloroquine in Tuberculosis (TB) (4 arms), sponsored by University of Zurich. Primary endpoints: Physical Examination at 30 days, Vital Signs at 30 days and 5 more. Started Jan 2022; status: recruiting.
02
Drugs
chloroquine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT05443178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05443178.